Last reviewed · How we verify
NCT04311944
Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD
NA trial testing Early fast-track care in HIV-1-infection in 242 participants. Status unknown.
28 February 2022
Quick facts
| Lead sponsor | Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 242 |
| Start date | 1 September 2020 |
| Primary completion | 28 February 2022 |
| Estimated completion | 29 May 2022 |
Drugs / interventions tested
- Early fast-track care
- Standard (deferred fast-track) care
Conditions studied
- HIV-1-infection — all drugs for HIV-1-infection →
Sponsor
Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic — full company profile →
Who can join
18 and older, any sex, with HIV-1-infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate the clinical efficacy of using earlier fast-track services compared to the standard of care in a clinical setting to improve retention in care and virologic suppression for patients who are initiating a dolutegravir-based antiretroviral therapy regimen.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Early initiation of fast-track care for persons living with HIV initiating dolutegravir-based regimens during a period of severe civil unrest in Port-au-Prince, Haiti: a pilot randomized trial.
Marc JB, Pierre S, Ducatel O, Homeus F, et al · · 2025 · cited 2× · PMID 39924611 · DOI 10.1002/jia2.26419
Verify or expand the search:
- PubMed search for NCT04311944
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV-1-infection
Currently open trials in the same condition.
- NCT07293559 — Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States · recruiting
- NCT06919016 — A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by DV701B1.1- · Phase 1 · active not recruiting
- NCT06554717 — Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV · Phase 2 · recruiting
- NCT06774872 — Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Succes · Phase 2 · recruiting
- NCT06890988 — Ending the Epidemic Interventions in the Dental Setting - UH3 · NA · recruiting
Other Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic trials
Trials by the same sponsor.
- NCT04311957 — Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults · Phase 4 · unknown
- NCT03405194 — Same-Day Treatment With Genvoya vs. EFV/TDF/3TC · NA · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04311944 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic
- Last refreshed: 31 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04311944.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing